A Phase 1b Trial to Evaluate Safety of MB097 in Combination With Pembrolizumab in Melanoma Patients
Status:
ACTIVE_NOT_RECRUITING
Trial end date:
2027-08-01
Target enrollment:
Participant gender:
Summary
A Phase 1b study to evaluate the safety and tolerability of MB097 given in combination with pembrolizumab in patients with melanoma who demonstrate primary resistance to anti-PD1 therapy.